Brent Kramer, MD
Ophthalmology · Sioux Falls, SDNPI 1689106460
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.3%), other and food and beverage — rather than concentrated in one kind of arrangement. Glaukos Corporation accounts for 68.2% of it on its own, with 23 other manufacturers making up the rest. Among ophthalmology clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 136 payments — averaging $188.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$18K
- Alcon$2K
- Dompe US, Inc.$2K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Carl Zeiss Meditec, Inc.$923
- Oyster Point Pharma, Inc.$451
- plus $2K from 18 others
Across 63 payments — averaging $1719.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$65K
- Alcon Research LLC$42K
- Bausch & Lomb Americas Inc.$1K
What the payments were for
- Consulting fees$11,12043%
- Speaking & faculty fees$390%
- Travel & lodging$4972%
- Food & beverage$6,46825%
- Education$980%
- Other$7,47529%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 25 | $17,520 |
| Alcon | 25 | $1,859 |
| Dompe US, Inc. | 12 | $1,513 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $1,191 |
| Carl Zeiss Meditec, Inc. | 2 | $923 |
| Oyster Point Pharma, Inc. | 8 | $451 |
| AbbVie | 9 | $221 |
| Novartis | 4 | $210 |
| Alcon Research LLC | 2 | $201 |
| Biotissue Holdings Inc. | 8 | $200 |
| Mallinckrodt Hospital Products Inc. | 5 | $196 |
| Harrow Eye, LLC | 4 | $190 |
| Kala Pharmaceuticals, Inc. | 1 | $128 |
| Bausch & Lomb Americas Inc. | 3 | $127 |
| Thea Pharma Inc. | 1 | $126 |
| Rayner Intraocular Lenses Limited | 4 | $124 |
| Eyepoint US, Inc. | 1 | $124 |
| Amgen | 5 | $111 |
| Sight Sciences, Inc. | 4 | $103 |
| Ocular Therapeutix, Inc. | 1 | $53 |
| Sun Pharmaceutical Industries Inc. | 2 | $45 |
| Rxsight Inc | 1 | $39 |
| Beaver-visitec International, Inc. | 1 | $24 |
| Tarsus Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Travoprost Intraocular Implant - iDose$6,564
- KXL System$1,797
- Oxervate$1,314
- Tecnis Simplicity$900
- ARTEVO 800$880
- IOLMaster 700$880
- VERACITY SURGICAL$880
- CE-marked KXLA system$825
- Clareon$567
- Centurion$449
- iStent inject W$399
- ARGOS$304
- iStent$297
- TYRVAYA$270
- Unity$267
- IACCESS$188
- Photrexa$188
- iStent Inject Trabecular Micro-Bypass System$171
- AIR OPTIX$156
- INVELTYS$128
How this compares
$25,697 in reported general payments places this provider in the 90th percentile of 52 ophthalmology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 414 | $18,289 |
| TyrvayaVarenicline Tartrate | 17 | $11,134 |
| MoxifloxacinMoxifloxacin Hcl | 190 | $4,434 |
| Bromfenac Sodium | 20 | $3,375 |
| Ketorolac Tromethamine | 111 | $1,826 |
| Fluorometholone | 18 | $1,596 |
| Ofloxacin | 105 | $1,318 |
| ValacyclovirValacyclovir Hcl | 20 | $686 |
| Brimonidine Tartrate | 11 | $598 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 39 | $486 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $472 |
| ErythromycinErythromycin Base | 16 | $149 |
| Tobramycin | 14 | $127 |
| Tramadol Hcl | 21 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Oyster Point Pharma, Inc.Tyrvaya | $451 | $11,13417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 52 ophthalmology providers in South Dakota.
Other ophthalmology in Sioux Falls
- Vance ThompsonSioux Falls$1.9M
- John BerdahlSioux Falls$1.2M
- Daniel TerveenSioux Falls$521K
- Tanner FergusonSioux Falls$49K
- Alison TendlerSioux Falls$31K
- Jed AssamSioux Falls$18K
- Anthony MaiSioux Falls$8K
- Ryan GeraetsSioux Falls$7K
- Eric ThomasSioux Falls$7K
- Yujia ZhouSioux Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.